The phase 3 trial was designed to evaluate the effectiveness of switching to camizestrant in combination with a CDK 4/6 inhibitor after the emergence of an ESR1 mutation, a key driver of resistance to endocrine therapy, according to a Feb. 26 news release from the company.
The results showed a statistically significant improvement in progression-free survival. While secondary end points — including overall survival and time to second disease progression — remain under evaluation, initial data showed a trend toward improved outcomes with the camizestrant combination.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
